Rangering i aksjer
#24756
Established in 2006 and headquartered in Tokyo, Japan, Solasia Pharma K.K. is... Established in 2006 and headquartered in Tokyo, Japan, Solasia Pharma K.K. is dedicated to the development and commercialization of oncology treatments throughout Japan and other parts of Asia. The company's marketed products include SP-03 (episil oral liquid), designed for the protection and relief of oral pain and inflammation (mucositis/stomatitis) resulting from cancer chemotherapy and radiation. Additionally, they offer SP-01 (Sancuso), a transdermal patch that delivers granisetron, an anti-emetic, into the bloodstream to manage chemotherapy-induced nausea and vomiting. Solasia Pharma's development pipeline features SP-02 (Darinaparsin), a mitochondrial-targeted agent that has successfully completed Phase III clinical trials for a range of hematologic and solid cancers. Also in Phase III clinical study is SP-05 (Arfolitixorin), which aims to bolster the anti-tumor effectiveness of fluorouracil in various cancers, including pancreatic, breast, stomach, and head and neck cancers. In its pre-clinical stage, SP-04 is being developed to address chemotherapy-induced peripheral neuropathy.
Handel Solasia Pharma K.K. (4597)
Pris 4597 pris med markedsverdi på B
Markedsverdi av Solasia Pharma K.K.(4597)
Markedsverdi: $57.00M
Per August 2026 har Solasia Pharma K.K. en markedsverdi på $57.00M. Dette gjør Solasia Pharma K.K. til det 24756th mest verdifulle selskapet i verden basert på markedsverdi ifølge våre data. Markedsverdi er den totale markedsverdien av et børsnotert selskaps utestående aksjer og brukes vanligvis til å måle hvor mye et selskap er verdt.
Markedsverdihistorikk for Solasia Pharma K.K. fra 2017 til 2026
4597 sammenlignet med topp 5 mest populære stocks
| Pris på 4597 |
|
Eiendel B |
Markedsverdi for B |
Resultater |
|
|
|
|
$5.257T
|
+9,222,689.99%
|
|
|
|
|
$4.599T
|
+8,067,923.66%
|
|
|
|
|
$4.107T
|
+7,204,622.15%
|
|
|
|
|
$3.577T
|
+6,275,948.87%
|
|
|
|
|
$2.807T
|
+4,925,127.16%
|
